The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

Author： Kristensen L. E.   Christensen R.   Bliddal H.   Geborek P.   Danneskiold-Samsøe B.   Saxne T.  

Publisher： Informa Healthcare

ISSN： 0300-9742

Source： Scandinavian Journal of Rheumatology, Vol.36, Iss.6, 2007-01, pp. : 411-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment

By Brodszky V.   Pentek M.   Gulacsi L.  

Scandinavian Journal of Rheumatology, Vol. 37, Iss. 5, 2008-01 ,pp. : 399-400

Informa Healthcare

Access to resources Recommend Favorite

Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

By Lee YH   Woo J-H   Choi SJ   Ji JD   Bae S-C   Song GG  

Scandinavian Journal of Rheumatology, Vol. 39, Iss. 4, 2010-08 ,pp. : 271-278

Informa Healthcare

Access to resources Recommend Favorite

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

By Li Sophia   Kaur Primal   Chan Virginia   Berney Steven  

Clinical Rheumatology, Vol. 28, Iss. 7, 2009-07 ,pp. : 787-791

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis: ATTEST–AMPLE network randomized trial

By Christensen Robin   Tarp Simon   Furst Daniel E   Kristensen Lars E   Bliddal Henning  

International Journal of Clinical Rheumatology, Vol. 8, Iss. 6, 2013-12 ,pp. : 647-655

Future Medicine

Access to resources Recommend Favorite

Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis

By Morozzi G.   Fabbroni M.   Bellisai F.   Cucini S.   Simpatico A.   Galeazzi M.  

Clinical Rheumatology, Vol. 26, Iss. 8, 2007-08 ,pp. : 1335-1338

Springer Publishing Company

Access to resources Recommend Favorite